[
    [
        {
            "time": "2021-12-31",
            "original_text": "贝达药业(300558.SZ)拟以2230万元剥离贝莱特以聚焦公司核心优势业务发展",
            "features": {
                "keywords": [
                    "贝达药业",
                    "剥离",
                    "贝莱特",
                    "核心业务",
                    "聚焦"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)拟以2230万元剥离贝莱特以聚焦公司核心优势业务发展",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "贝达药业(300558.SZ)：子公司拟2230万元向医药科技转让所持贝莱特100%的股权 资产异常",
            "features": {
                "keywords": [
                    "贝达药业",
                    "子公司",
                    "股权转让",
                    "贝莱特",
                    "资产异常"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：子公司拟2230万元向医药科技转让所持贝莱特100%的股权 资产异常",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "2021年度策略行业策略：医药黄金时代行情不会缺席 2021只是更加极致聚焦",
            "features": {
                "keywords": [
                    "2021年度策略",
                    "医药",
                    "黄金时代",
                    "聚焦"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "2021年度策略行业策略：医药黄金时代行情不会缺席 2021只是更加极致聚焦",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        }
    ]
]